Ally Bridge Group NY LLC Has $5.66 Million Holdings in IsoPlexis Co. (NASDAQ:ISO)

Ally Bridge Group NY LLC lessened its holdings in shares of IsoPlexis Co. (NASDAQ:ISOGet Rating) by 6.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,650,118 shares of the company’s stock after selling 120,000 shares during the period. IsoPlexis comprises 4.2% of Ally Bridge Group NY LLC’s holdings, making the stock its 11th largest holding. Ally Bridge Group NY LLC owned 4.23% of IsoPlexis worth $5,660,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ISO. Northern Trust Corp acquired a new position in shares of IsoPlexis during the 4th quarter worth approximately $644,000. Sio Capital Management LLC bought a new stake in shares of IsoPlexis during the 4th quarter worth approximately $4,549,000. Ghisallo Capital Management LLC bought a new stake in shares of IsoPlexis during the 4th quarter worth approximately $184,000. Perceptive Advisors LLC bought a new stake in shares of IsoPlexis during the 4th quarter worth approximately $37,637,000. Finally, Parian Global Management LP bought a new stake in shares of IsoPlexis during the 4th quarter worth approximately $1,124,000. Institutional investors and hedge funds own 48.70% of the company’s stock.

Insider Activity

In other IsoPlexis news, SVP Richard W. Rew II purchased 20,000 shares of the business’s stock in a transaction dated Thursday, August 25th. The shares were bought at an average price of $1.99 per share, for a total transaction of $39,800.00. Following the completion of the acquisition, the senior vice president now owns 20,000 shares in the company, valued at $39,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other IsoPlexis news, SVP Richard W. Rew II purchased 20,000 shares of the business’s stock in a transaction dated Thursday, August 25th. The shares were bought at an average price of $1.99 per share, for a total transaction of $39,800.00. Following the completion of the acquisition, the senior vice president now owns 20,000 shares in the company, valued at $39,800. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sean Mackay purchased 15,000 shares of the business’s stock in a transaction dated Thursday, August 25th. The shares were acquired at an average price of $1.99 per share, for a total transaction of $29,850.00. Following the acquisition, the chief executive officer now owns 914,366 shares of the company’s stock, valued at approximately $1,819,588.34. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 65,506 shares of company stock valued at $128,406. Insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on ISO. Morgan Stanley downgraded shares of IsoPlexis from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $8.00 to $5.00 in a report on Thursday, August 11th. SVB Leerink downgraded shares of IsoPlexis from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $8.00 to $3.00 in a research note on Thursday, August 11th.

IsoPlexis Trading Up 2.8 %

Shares of NASDAQ:ISO opened at $2.18 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 10.20 and a quick ratio of 6.78. The firm has a 50 day simple moving average of $2.64 and a 200 day simple moving average of $2.80. IsoPlexis Co. has a one year low of $1.62 and a one year high of $16.95.

IsoPlexis (NASDAQ:ISOGet Rating) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.02). The company had revenue of $4.01 million during the quarter, compared to the consensus estimate of $5.64 million. IsoPlexis had a negative net margin of 535.02% and a negative return on equity of 159.40%. As a group, research analysts anticipate that IsoPlexis Co. will post -2.13 EPS for the current fiscal year.

IsoPlexis Profile

(Get Rating)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea.

Read More

Want to see what other hedge funds are holding ISO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IsoPlexis Co. (NASDAQ:ISOGet Rating).

Institutional Ownership by Quarter for IsoPlexis (NASDAQ:ISO)

Receive News & Ratings for IsoPlexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoPlexis and related companies with MarketBeat.com's FREE daily email newsletter.